PLP (139-151)

PLP (139-151) is amino acid residue 139 to 151 of myelin proteolipid protein (PLP) used to induce experimental autoimmune encephalomyelitis (EAE).

Product information

CAS Number: 131334-43-5

Molecular Weight: 1537.79

Formula: C72H104N20O16S

Chemical Name: (3S)-3-{[(1S)-5-amino-1-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}pentyl]carbamoyl}-3-{[(2S)-1-[(2S)-2-{2-[(2S)-2-[(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(1H-imidazol-5-yl)propanamido]-3-sulfanylpropanamido]-4-methylpentanamido]acetamido}hexanamido]-3-(1H-indol-3-yl)propanamido]-4-methylpentanamido]acetamido}-3-(1H-imidazol-5-yl)propanoyl]pyrrolidin-2-yl]formamido}propanoic acid

Smiles: CC(C)C[C@H](NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CN=CN1)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1C=CC=CC=1)C(O)=O

InChiKey: VTBYVGRYDXYLHZ-UVIWMAFZSA-N

InChi: InChI=1S/C72H104N20O16S/c1-40(2)25-51(63(98)80-36-60(94)84-55(30-45-34-77-39-82-45)71(106)92-24-14-21-58(92)70(105)89-54(31-61(95)96)68(103)85-50(20-11-13-23-74)66(101)90-56(72(107)108)27-42-15-6-5-7-16-42)86-67(102)53(28-43-32-78-48-18-9-8-17-46(43)48)88-65(100)49(19-10-12-22-73)83-59(93)35-79-64(99)52(26-41(3)4)87-69(104)57(37-109)91-62(97)47(75)29-44-33-76-38-81-44/h5-9,15-18,32-34,38-41,47,49-58,78,109H,10-14,19-31,35-37,73-75H2,1-4H3,(H,76,81)(H,77,82)(H,79,99)(H,80,98)(H,83,93)(H,84,94)(H,85,103)(H,86,102)(H,87,104)(H,88,100)(H,89,105)(H,90,101)(H,91,97)(H,95,96)(H,107,108)/t47-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: H2O : ≥ 50 mg/mL (32.51 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Severe clinical and histological EAE could be induced by adoptive transfer of the peptide-specific T cell line and 3 of 4 T cell clones. The T cell line/clones all responded strongly to PLP (139-151) in in vitro proliferative assays. Line SPL and all of the clones show strong proliferative response to the whole PLP molecule and to PLP (139-151).

In Vivo:

PLP (139-151) induces acute experimental allergic encephalomyelitis (EAE) in SJL/J mice. Beginning on Day 9, the mice treated with PLP (139-151) show signs of EAE and the disease progressed rapidly to paralysis. Central nervous system inflammation, edema, gliosis, and demyelination are found in all mice killed between Days 10 and 28. Young male SJL mice immunized with a major encephalitogenic peptide of myelin, PLP 139-151, develop initial clinical and histological symptoms of EAE with a severity similar to age-matched females; however, unlike females, male mice does not relapse. Significant T cell proliferation to PLP 139-151, but not to other PLP and myelin basic protein (MBP) epitopes, is observed in both males and females during the initial episode, recovery, and first relapse of clinical disease.

Products are for research use only. Not for human use.